Truvian Health announced it is redefining the current global infrastructure through its novel platform, creating a world where central laboratory equivalent blood tests are available anywhere you go. Truvian raised $74 million in funding to be used in part to secure US Food and Drug Administration (FDA) clearance for its blood testing platform. The latest funding round was co-led by Wittington Ventures and Great Point Ventures, with strong support from existing investors, including DNS Capital, Medical Excellence Capital, Tao Capital, TYH Capital, and 7wireVentures.
Adults often skip routine blood testing since it is usually considered complex. This leads to delayed to medical intervention or missed diagnoses leading to significant and avoidable costs to the US healthcare system. And Truvian’s automated benchtop platform promises to change this by enabling simple, accurate, and comprehensive routine blood tests to be performed in clinics, doctor’s offices and pharmacies. Over the past year, Truvian has presented data from multiple independent clinical studies demonstrating that results from its platform are equivalent to those produced in a central laboratory across a large panel of tests.
Late last year, Shoppers Drug Mart led an onsite evaluation of Truvian which compared to the results from Truvian’s platform to a traditional central laboratory. And the results between Truvian and the central laboratory were concordant, emphasizing the potential utility of Truvian’s solution.
Truvian is the first company to share evidence that demonstrates a multi-modal platform can achieve clinical performance equivalent to the central laboratory across a large panel of tests with a single sample. So far, Truvian’s integrated platform has been evaluated on over 50,000 samples across 5,000 donors while achieving a platform run reliability rate of greater than 98%. Truvian has also scaled its instrument and consumable manufacturing capabilities to initiate its clinical trials and early partner access programs.
KEY QUOTES:
“Working with our government partners, we believe in advancing technology to better support patient care, including comprehensive blood testing. Truvian’s novel platform, combined with the convenience of accessing care in pharmacy, will be an amazing step forward in making care more accessible and convenient for patients.”
— Jeff Leger, president at Shoppers Drug Mart
“These new investments and strategic partnerships further validate our goal to bring convenient, comprehensive testing to primary care, enabling patients and their doctors to make timely decisions affecting their health. We are on the cusp of delivering what the world needs to counter today’s non-communicable disease burden and unsustainable healthcare costs.”
— Jay Srinivasan, chief executive officer of Truvian
